Bristol Myers Squibb Company $BMY Shares Bought by Nisa Investment Advisors LLC

Nisa Investment Advisors LLC increased its holdings in shares of Bristol Myers Squibb Company (NYSE:BMY) by 10.3% during the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 558,016 shares of the biopharmaceutical company’s stock after acquiring an additional 52,106 shares during the period. Nisa Investment Advisors LLC’s holdings in Bristol Myers Squibb were worth $30,099,000 as of its most recent SEC filing.

Other large investors also recently bought and sold shares of the company. Darwin Wealth Management LLC purchased a new stake in shares of Bristol Myers Squibb in the second quarter valued at approximately $25,000. Harbor Capital Advisors Inc. grew its stake in Bristol Myers Squibb by 107.2% in the 3rd quarter. Harbor Capital Advisors Inc. now owns 605 shares of the biopharmaceutical company’s stock valued at $27,000 after acquiring an additional 313 shares during the period. Beacon Financial Strategies CORP acquired a new stake in Bristol Myers Squibb in the 4th quarter valued at $38,000. KERR FINANCIAL PLANNING Corp acquired a new position in Bristol Myers Squibb during the third quarter worth $35,000. Finally, JPL Wealth Management LLC purchased a new position in Bristol Myers Squibb during the third quarter valued at $36,000. Institutional investors and hedge funds own 76.41% of the company’s stock.

Analyst Upgrades and Downgrades

A number of analysts have recently commented on BMY shares. Citigroup boosted their target price on shares of Bristol Myers Squibb from $60.00 to $64.00 and gave the stock a “neutral” rating in a research note on Friday, February 6th. Truist Financial set a $65.00 price objective on Bristol Myers Squibb in a report on Wednesday, December 3rd. Leerink Partners raised their target price on Bristol Myers Squibb from $54.00 to $60.00 and gave the company an “outperform” rating in a research report on Tuesday, January 13th. Wells Fargo & Company reissued an “outperform” rating and issued a $60.00 price objective (up from $55.00) on shares of Bristol Myers Squibb in a research note on Friday, February 6th. Finally, HSBC raised their price objective on Bristol Myers Squibb from $53.00 to $60.00 and gave the company a “hold” rating in a report on Tuesday, March 17th. Nine analysts have rated the stock with a Buy rating, twelve have assigned a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the company has an average rating of “Hold” and a consensus price target of $61.41.

Key Headlines Impacting Bristol Myers Squibb

Here are the key news stories impacting Bristol Myers Squibb this week:

• Positive Sentiment: Phase‑3 adolescent win for Camzyos strengthens BMY’s cardiovascular franchise — the SCOUT‑HCM trial met its primary endpoint with robust efficacy and no new safety signals, supporting label expansion into younger patients and longer commercial runway for the drug. Camzyos Adolescent Trial Success Might Change The Case For Investing In Bristol-Myers Squibb (BMY)
• Positive Sentiment: FDA approval for a Hodgkin’s lymphoma combination therapy provides an immediate commercial lift and validates oncology execution — another approved product can help offset patent cliffs elsewhere. Bristol-Myers Squibb Gets FDA Approval for Hodgkin’s Lymphoma Treatment
• Positive Sentiment: Value/income investor interest — Ariel Global Fund re‑added BMY citing pipeline strength and attractive valuation, which could signal renewed institutional demand. Ariel Global Fund Re-Added Bristol-Myers Squibb Company (BMY) on Pipeline Strength and Attractive Valuation
• Neutral Sentiment: Analyst/education pieces (Zacks, Yahoo) highlight potential upside from earnings surprises using Earnings ESP and note BMY’s recent outperformance relative to its history, but these are directional signals rather than new fundamentals. Bristol Myers Squibb (BMY) Ascends But Remains Behind Market: Some Facts to Note
• Neutral Sentiment: Market reports project growth in oncology and kidney cancer drug markets through 2030, underlining long‑term addressable market tailwinds for BMY but not immediate revenue changes. Kidney Cancer Drugs Market to Grow by $2 Billion During 2026-2030
• Negative Sentiment: Some outlets note mixed analyst sentiment and questions around near‑term execution; investors should weigh recent approval and trial wins against prior earnings misses and heavy leverage on the balance sheet. Bristol-Myers Squibb (BMY) faces mixed analyst sentiment despite strong momentum in healthcare industry

Bristol Myers Squibb Stock Performance

NYSE BMY opened at $60.56 on Wednesday. The company has a debt-to-equity ratio of 2.32, a quick ratio of 1.14 and a current ratio of 1.26. The stock’s fifty day moving average is $59.03 and its two-hundred day moving average is $52.45. The firm has a market capitalization of $123.65 billion, a P/E ratio of 17.55, a price-to-earnings-growth ratio of 0.17 and a beta of 0.26. Bristol Myers Squibb Company has a fifty-two week low of $42.52 and a fifty-two week high of $62.89.

Bristol Myers Squibb (NYSE:BMY) last issued its earnings results on Thursday, February 5th. The biopharmaceutical company reported $1.26 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $1.65 by ($0.39). The company had revenue of $12.50 billion during the quarter, compared to analyst estimates of $12.24 billion. Bristol Myers Squibb had a return on equity of 69.65% and a net margin of 14.64%.The firm’s revenue was up 1.3% compared to the same quarter last year. During the same period last year, the business earned $1.67 earnings per share. Bristol Myers Squibb has set its FY 2026 guidance at 6.050-6.350 EPS. On average, research analysts anticipate that Bristol Myers Squibb Company will post 6.74 earnings per share for the current year.

Bristol Myers Squibb Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Friday, May 1st. Shareholders of record on Thursday, April 2nd will be paid a dividend of $0.63 per share. The ex-dividend date of this dividend is Thursday, April 2nd. This represents a $2.52 annualized dividend and a yield of 4.2%. Bristol Myers Squibb’s dividend payout ratio (DPR) is 73.04%.

Bristol Myers Squibb Profile

Bristol Myers Squibb is a global biopharmaceutical company headquartered in Princeton, New Jersey, focused on discovering, developing and delivering medicines for serious diseases. The company’s core activities include research and development, clinical development, manufacturing and commercialization of prescription pharmaceuticals across multiple therapeutic areas. BMS concentrates on advancing therapies in oncology, hematology, immunology, cardiovascular disease and specialty areas through both small molecules and biologics.

BMS’s marketed portfolio and late‑stage pipeline reflect a strong emphasis on cancer and immune‑mediated conditions.